Treatment of Anogenital Warts: Siriraj Hospital Experience
Article Sidebar
Main Article Content
Abstract
Objectives: To demonstrate the characteristics, treatment modalities and outcomes in the women presenting with Anogenital Warts (AGW) at Female STI Clinic, Siriraj Hospital.
Materials and Methods: The outcomes of treatment in the patients who had complete followed up at Siriraj Female STI clinic in 2016 were reviewed. The patients with immunocompromised conditions such as systemic lupus erythematosus and human immunodeficiency virus infection were excluded from this study.
Results: Two hundred and four of 217 women with AGW were eligible for this study. The mean age was 24.6±5.2 years. Most of them were married and had sexual monogamy. Education levels were similar. Most of the AGWs were located outside the vagina and with ≤ 5 lesions (range 1-20). The diameter of warts were between 1 and 5cm. The treatment modalities were 85 % trichloroacetic acid (TCA) 131 (64.3%), 5% imiquimod 57 (27.9%), cryotherapy 8 (3.9%) and surgery 8 (3.9%). The median periods of treatment were 4, 8, 5 and 1 weeks for 85 % TCA, 5% Imiquimod, Cryotherapy and Surgery, respectively. Treatment modalities were changed in the groups of 85% TCA and 5% Imiquimod, for 16.0% and 1.8%, respectively. Recurrence at 3 months after being cured was highest in the groups of 85% TCA (13.0%).
Conclusion: Our results showed that 85 % TCA, which is widely available, need four applications with 13% recurrence rate. Imiquimod took longer time for treatment but was associated with less recurrent. Cryotherapy and Surgery showed promising results but the data were limit.
Article Details
References
Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39.
Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 2000;163:503-8.
Bechtel MA, Trout W. Sexually transmitted diseases. Clin Obstet Gynecol 2015;58:172-84.
National Disease Surveillance Report (Report 506) [Internet]. 2019 [cited 20 December 2019]. Available from: http://www.boe.moph.go.th/boedb/surdata/index.php.
Qi SZ, Wang SM, Shi JF, Wang QQ, Chen XS, Sun LJ, et al. Human papillomavirus-related psychosocial impact of patients with genital warts in China: a hospital-based cross-sectional study. BMC Public Health 2014;14:739.
Chayachinda C, Thamkhantho M, Chalermchockcharoenkit A, Nuengton C, Thipmontree W. Characteristics of clients at the Siriraj Female STD Clinic during 2011-2015. Siriraj Medical Bulletin 2018;11:182-9.
Gunter J. Genital and perianal warts: new treatment opportunities for human papillomavirus infection. Am J Obstet Gynecol 2003;189(3 Suppl):S3-11.
Chayachinda C, Boriboonhirunsarn D, Thamkhantho M, Nuengton C, Chalermchockcharoenkit A. Number of external anogenital warts is associated with the occurrence of abnormal cervical cytology. Asian Pac J Cancer Prev 2014;15:1177-80.
Lopaschuk CC. New approach to managing genital warts. Can Fam Physician 2013;59:731-6.
Komericki P, Akkilic-Materna M, Strimitzer T, Aberer W. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Sex Transm Dis 2011;38:216-8.
Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002;47(4 Suppl):S205-8.
Carrasco D, vander Straten M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions. J Am Acad Dermatol 2002;47(4 Suppl):S212-6.
Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(RR-03):1-137.
Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, et al. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada. J Obstet Gynaecol Can 2018;40:1635-45.
Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill 2018;23.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015;372:711-23.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
Choi H. Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study. Int Braz J Urol 2019;45:361-8.